Immunotoxins with decreased immunogenicity and improved activity

Leukemia and Lymphoma

Volumn 52, Issue SUPPL. 2, 2011, Pages 87-90

  Pastan, Ira ^a   Onda, Masanori ^a   Weldon, John ^a   Fitzgerald, David ^a   Kreitman, Robert J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

hairy cell leukemia; Recombinant immunotoxins

Indexed keywords

ALANINE; EPITOPE; IMMUNOTOXIN; IMMUNOTOXIN BL 22; IMMUNOTOXIN HA22 LR; MOXETUMOMAB PASUDOTOX; PROTEINASE; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG POTENCY; EPITOPE MAPPING; HUMAN; IMMUNOGENICITY; LEUKEMIA CELL; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR XENOGRAFT;

ANIMALS; EPITOPES, B-LYMPHOCYTE; HUMANS; IMMUNOTOXINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MUTATION;

EID: 79957468477     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.573039     Document Type: Article

References (9)

1. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-237. (Pubitemid 46706511)
2. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy- resistant hairy-cell leukemia. N Engl J Med 2001;345: 241-247. (Pubitemid 32695063)
3. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23: 6719-6729. (Pubitemid 46190267)
4. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-5149. (Pubitemid 47502082)
5. Kreitman RJ, Hassan R, FitzGerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009;15:5274-5279.
6. Onda M, Nagata S, Fitzgerald DJ, et al. Characterization of the B cell epitopes associated with a truncated form of pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006;177:8822-8834. (Pubitemid 44893849)
7. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 2008;105:11311-11316.
8. Weldon JE, Xiang L, Chertov O, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009;113: 3792-3800.
9. Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, Pastan I. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J Immunother 2010;33:297-304.